Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13890084 | 0.90 | L3MBTL1 (0.56) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL10803219 | 0.86 | MGAM (0.44) | L3MBTL1KMT2APOLBGAAMGAM | |
| SCHEMBL580234 | 0.86 | L3MBTL1 (0.53) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL8719366 | 0.85 | MGAM (0.52) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL9507708 | 0.84 | L3MBTL1 (0.51) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL16876657 | 0.84 | MGAM (0.43) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| Ethane SCHEMBL28182021 | 0.84 | MGAM (0.43) | L3MBTL1KMT2APOLBGAAMGAM | |
| SCHEMBL25405489 | 0.82 | CYP1A2 (0.52) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL2457733 | 0.82 | MGAM (0.41) | L3MBTL1KMT2APOLBCYP1A2GAA | |
| SCHEMBL15899556 | 0.82 | ALDH1A1 (0.48) | L3MBTL1KMT2APOLBCYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-14 | — | — | US | disclosed |
| US-9650384-B2 | Substituted pyrimidine compounds and methods of use and manufacture | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650384-B2 | Substituted pyrimidine compounds and methods of use and manufacture | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-05-16 | — | — | US | disclosed |
| US-9550745-B2 | Method for preparing 4-aminobut-2-enolides | BAYER CROPSCIENCE AG (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-02-11 | — | — | US | disclosed |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-02-11 | — | — | US | disclosed |
| WO-2016022881-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20120323023-A1 | METHOD FOR PREPARING 4-AMINOBUT-2-ENOLIDES | BAYER CROPSCIENCE AG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8273904-B2 | Method for preparing 4-aminobut-2-enolides | BAYER CROPSCIENCE AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| US-20100190990-A1 | Method for Producing 4-Aminobut-2-Enolides | BAYER CROPSCIENCE AG (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| EP-1989179-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | L3MBTL1 3568/4885KMT2A 3770/4885POLB 2876/4885 |
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DHFR, FOLR1, DPYD | L3MBTL1 3712/4885KMT2A 1754/4885POLB 422/4885 |
| US-20100190990-A1 | Method for Producing 4-Aminobut-2-Enolides | TUBB4B, UGT2B7, TUBB4A | L3MBTL1 4232/4885KMT2A 2123/4885POLB 248/4885 |
| US-20120323023-A1 | METHOD FOR PREPARING 4-AMINOBUT-2-ENOLIDES | UGT2B7, TUBB4B, CYP1B1 | L3MBTL1 4471/4885KMT2A 2274/4885POLB 180/4885 |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DHFR, FOLR1, DPYD | L3MBTL1 3712/4885KMT2A 1754/4885POLB 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.